key: cord-0037418-yk9tjwno
authors: Wardle, E. Nigel
title: Cell Defence and Survival
date: 2009-03-16
journal: Guide to Signal Pathways in Immune Cells
DOI: 10.1007/978-1-60327-538-5_11
sha: a609f2ee5a32116fb0e2d2a1d0adb9a27273aaf8
doc_id: 37418
cord_uid: yk9tjwno

Central to immune defence mechanisms is the role of transcription factor nuclear factor kappa B (NF-kB). This is a complex biochemical topic with ever more controls revealed. NF-kB determines the production of proinflammatory cytokines and chemokines. Pharmacologists step in with possible means of control. Other systems involved in defence include the cyclooxygenase 2 (Cox-2) enzyme and perioxisome proliferator-activated receptors. Insulin receptor activation needs to be seen in context. The mTOR system directs uptake of nutrients by cells. mTOR is suppressed by rapamycin, whose usage is now quite considerable in the control of transplant rejection.

and (f) viruses. Intracellular oxidants [11, 12] help the I k B inhibitors to be dissociated from the NF-k B units. Hence, intracellular reductants like glutathione and thioredoxin have differential roles in the redox regulation of target proteins, and S-nitrosylation can inhibit NF-k B DNA binding [13] . Yet, within nuclei it is the more reducing environment there that enables NF-k B RHDs to bind onto the DNA. As you will now expect, zymosan proinflammatory agent stimulates NF-k B, causing release of IL-8 so that neutrophils are attracted [14] . That process can be inhibited by nitric oxide (NO) or by IL-10 inhibition of NF-k B [15] . Examination of synovial tissue in rheumatoid arthritis shows marked expression of NF-k B1 at sites adjacent to the cartilage-pannus junction. NF-kB activation upregulates chemokines and adhesion molecules and neutrophils and macrophones are then recruited.

Extra comment about Nemo (I k B kinase-g , IKK g ) is appropriate as this is a developing field [16] . Nemo has two coiled domains, CC1 and CC2, and a leucine zipper. Nemo interacts with many proteins involved in NF-k B activation. It is polyubiquitinated but on differing lysine residues according to the stimulus [17] . Its potential is also influenced by sumoylation and phosphorylation.

The IL-1 b and TNF a cytokine receptors connect via upstream kinases to the activation of NF-k B [17, 18] . The two IKK kinases a and b have an activation loop like that of the mitogen-activated protein kinase kinase (MAPKK) proteins, which bears two serines that are phosphorylated in response to IL-1 or TNF a . Cytokine IL-1 can activate either IKK b or the IKK a .

As shown in Fig. 11 .1a , serine-threonine kinases IKK a and IKK b form homoor heterodimers in conjunction with stabilising protein Nemo (the NF-k B essential modulator), also termed IKK g [4, 19] . Binding of Nemo to Lys63-polyUb-RIP1 forms the active kinase complex IKK g , IKK b -P , IKK a -P that phosphorylates the inhibitor unit I k B a [20] , which then dissociates and is destroyed by ubiquitination. Accordingly, NF-k B as p50/RelA is free to enter nuclei. Oscillations in intranuclear NF-k B coupled to cycles of phosphorylation of RelA and I k B are required for NF-k B-dependent gene expression [21] . As revealed in Table 11 .1 , NF-k B activates a range of genes relevant to inflammation and innate immunity. There are genes for the cytokines and chemokines and for regulation of the cell cycle, survival, adhesion and invasiveness. Both apoptotic and antiapoptotic genes are induced. Genes with a role in feedback regulation of the NF-k B, such as I k B a and A20, are induced early. What does A20 protein do? It inhibits the IKK complex, it inhibits RIP ( Fig. 12.5 ) , and it inhibits TAK1 kinase. By inhibiting RIP, A20 stops TNF a -induced NF-k B activation, a step that requires Richard TAXIBI [21b] .

NF-k B is a key participant in multiple processes affecting the immune system and inflammation. It can interact with other TFs like Interferer Regulatory Factors (IRFs), signal transducers and activators of transcription (STATs) and the p53. Such promiscuity might explain the many roles of NF-k B in cell functions and fate [22] .

Hydrogen peroxide (from ROS) prolongs nuclear localization of NF-κB in activated cells [22b] . Fortunately, there is control by heat shock proteins HSP70 and HSP90 which regulate the IKK complex [22c] .

NF-k B plays a crucial role in inflammatory processes . Activation of p38 mitogenactivated protein kinase (MAP) kinase is well recognised to activate NF-k B [23] . If a single injection of lipopolysaccharide (LPS) is given intraperitoneally to mice, there is transient NF-k B activation in lung cell types. When the LPS is infused by a pump, there is widespread NF-k B activation and neutrophilic infiltration that begets lung injury following release of cytokine IL-8 ([MIP2] of mice) (Table 11 .1 ). Since the search is on for means of controlling ARDS (adult respiratory distress syndrome), an inhibitor of NF-k B could be found to reduce the lung inflammation. As for natural restraints PIAS [24] or MK2 [25] or Cezzare [22b] or CYLD deubiquitinating enzyme [26] block NF-k B activation. In resting neutrophils, RhoA GTPase inhibits the NF-k B to prevent TNF a production, and yet in LPS-stimulated neutrophils RhoA activates NF-k B and supports TNF a formation [27] .

The various homodimers and heterodimers of NF-k B are kept inactive by association with cytoplasmic inhibitory proteins [28] . They are I k B a , I k B b and I k B e and also the p105 and p100 precursors of p50 and p52 . Are there roles for the a -, b -, g -subunits of the IKK complex? [29] . IKK a is a histone H3 kinase that moves into nuclei to associate with the promoters of NF-k B-responsive genes [30, 31] . IKK a When Nemo/IKK g shuttles into nuclei, it creates feedback by repression of NF-k B gene expression. Nemo binds to other proteins like RIP and A20, and it regulates the IKK-related kinases IKK e and TBK1 (TANK binding kinase 1), which regulate interferon regulatory factors IRF3 and IRF7 .

As for IKK b , it can increase the activity of hypoxia-inducible factor 2 a (HIF2 a ) [33b] , so linking hypoxia to innate immunity and inflammation, and it activates a subset of (IFN g )-stimulated genes. For sure IKK b promotes the canonical pathway of NF-k B activation (Fig. 11 .1a) [29] . IKK b promotes the MAP kinases and cell proliferation (e.g. in skin keratinocytes) [29] . All the actions are tissue specific. Yet, IKK b exerts negative control over the production of IL-1 b [34] . Furthermore in some situations IKK b can suppress M1 host defence macrophages, so that it is antiinflammatory [34b] , but it promotes M2 immune regulation macrophages [34c] .

There is an alternative means of NF-k B activation [35] . Lymphotoxin, BAFF (B cell-activating factor), CD40L or RANKL (receptor activator of NF-k B ligand) activate NIK (NF-k B-inducing kinase), and it then acts on IKK a homodimer, whose target is NF-k B2, p100. Phosphorylation-dependent ubiquitination of the p100 is only partial. The N-terminal p52 is released and joins with RelB to enter the nuclei (Fig. 11 .2). This alternative path via p52/RelB enables BAFF (BLys) to activate B lymphocytes. The alternative path essentially provides organogenic chemokines [4] for the development of lymphoid tissue [36] and adaptive immunity. The NF-k B2 is also required for establishment of thymic central tolerance through an Aire-dependent pathway [37] . AIRE is the autoimmune regulator gene, and NF-k B2 is required in medullary thymic epithelial cells.

Whenever Rankl stimulates osteoclastogenesis, the NF-k B2 p100 path is implicated [38] . Acting on receptor rank on bone stromal cells, Rankl stimulates their NFATc1 and c-fos so that osteoclasts are formed. This activation is reinforced by Ca 2+ -calmodulin (CaM) stimulation of NFATc and of CaM kinase IV, which stimulates cAMP response element-binding protein (CREB) on the promoter for osteoclast marker genes. NIK has been shown by the study of mouse knockouts to control the activities of lymphocytes and osteoclasts in inflammatory arthritis [39] . NIK −/− mice have no peripheral lymph nodes, defective T and B cells and impaired Rankl-induced osteoclastogenesis. One might also be interested that when ultraviolet light acts on skin to cause immunosuppression by induction of Treg cells, Rankl on keratinocytes first stimulates Rank on Langerhans cells. Vitamin D 3 , which is immunosuppressive, also induces Rankl [40] .

All NF-k B activation pathways share the proteasome-mediated step ( Fig. 11 .1 ) that causes the degradation of the inhibitory proteins. Posttranslational modifications like phosphorylation [42] , acetylation [43] or prolyl isomerization modulate the activity of the p65 (or p50) subunits. Thus, acetylation of multiple lysine residues by p300/CBF acetyltransferases ( Fig. 4.8 ) modifies the behaviour of NF-k B components. Acetylation works as an intranuclear molecular switch [44] . Acetylation of p65 stops inhibition by I k B a and controls nuclear NF-k B. Oxidative stress, via its formation of H 2 O 2 , which enhances degradation of I k B a , enhances NF-k B activity [22b] ; thus, macrophages have increased production of cyclooxygenase 2 (Cox-2), prostaglandin E2 (PGE2), and matrix metalloproteinase 1 (MMP-1) [45] .

Activation of NF-k B-inducible genes (Table 11 .1 ) usually takes place by means of the p65/p50 DNA binding heterodimers of the classical pathway. Significant fluctuation in p50 levels can alter the abundance and composition of NF-k B complexes within a cell. When animals or cells are exposed to repeated small doses of LPS, the output of cytokines via NF-k B activation is thwarted, and the animals or cells show endotoxin tolerance . The explanation is that p50/p50 homodimers are formed instead of the p65/p50, and the consequence is suppression of NF-k B-inducible genes [46] . p65 has a transactivation domain, whereas p50 does not. p50/p50 homodimers (as produced by IL-10 or by protein kinase A) are inhibitory. Cells that are tolerant to endotoxin still respond to LPS with the degradation of I k B and nuclear translocation of p50 and p65. Yet, they cannot form IL-1 b . In such cells, it was found that RelB activation. Nemo also connects IKK complexes with IKK ε and TBK1 kinases. Monarch-1 suppresses the noncanonical NF-k B2 activation by causing proteasomal degradation of NF-k Binducing kinase ( NIK ). In T lymphocytes, the NF-k B2/p100 is a late-acting negative-feedback molecule affecting T cell receptor activation of the NF-k B [41] represses inflammatory gene expression [47] . Alternatively, in endotoxin tolerance, mobilization of Toll-like receptor 4 (TLR4) into lipid rafts is curtailed [48] .

p53 turns out to be a buffer of the innate immune system because p53 works as an antagonist of NF-k B to dampen chronic inflammation. p53 null macrophages show very high release of cytokines IL-1, IL-6 and IL-12 in response to LPS or IFN g . In fact, p53 downregulates Stat1 and proinflammatory cytokines [49] . In some cells, like leucocytes, I k B z negatively regulates intranuclear NF-k B activity [50] . We have noted how LPS exposure can attenuate TNF a gene transcription because NF-k B p50 homodimers bind to the TNF a promoter. In addition, LPS induces Bcl-3 (B cell lymphoma 3), which is an anti-inflammatory regulator [32b,51] . Bcl-3 is only located in cell nuclei, and it associates with p50/p50 homodimers and acts as a negative regulator of TLR signalling [52] . Bcl-3 reduces transcription of proinflammatory cytokines. It mediates some of the anti-inflammatory activities of IL-10 (Sect. 12.16) Bcl-6 is another transcriptional repressor protein. Repression by Bcl-6 is cell-type specific. Bcl-6 negatively regulates the expression of the NF-k B1 p105/p50 subunit. In macrophages, it negatively regulates the chemokines monocyte chemotactic peptide 1 (MCP-1) , MCP-3 and MIP-1 [53] . Indeed, in Bcl-6 −/− mice there is florid T helper lymphocyte Th2-mediated inflammation. Bcl-6 is essential for formation of germinal centres and for a normal antibody response [54] . Bcl-6 suppresses p53 expression in germinal centre B lymphocytes. Bcl-6 interacts with TF Miz-1 to suppress p21 and thus to allow proliferation of germinal centre B cells [55] . Activating mutations or chromosomal translocations that affect Bcl-6 are relevant to B cell lymphomas [56, 57] . The t (3;14) translocation affecting Bcl-6 is part of diffuse large B cell lymphoma (DLBCL).

One should consider the pharmacological means of control of NF-k B (Table 11 .2). Commensal gut bacteria like Bacteroides reduce the activity of NF-k B in gut Table 11 .2 Mediators and drugs that inhibit nuclear factor kappa B (NF-k B)

Interleukins 10 and 13 transforming growth factor-b IKBNS inhibitor, heat shock proteins HSP70 and HSP90, Nemo-binding domain peptide, CYLD Cyclic adenosine monophosphate (cAMP), glucocorticoids, oestrogen, melanocortins Nitric oxide late in macrophage activation a S-nitrosylation [9] T suppressor lymphocytes (Treg) tumor suppressor p53 Pharmacological Cyclopentenone prostaglandin 15-deoxy-PGJ2 , and the EETs, prostaglandin E2 (PGE2) Salicylates, acetylsalicyclic acid, sulindac (nonsteroidal anti-inflammatory, NSAID), sulfasalazine, mesalamine Antioxidants: vitamin E, N -acetylcysteine, taurine-chloramine, lipoic acid Lipoxin A4, pyrolidinedithiocarbamate, conjugated linoleic acid (CLA) PPAR g agonists like the thiazolidinediones (TZDs) and PPAR a Immunosuppressant cyclosporin 1,25(OH)2 vitamin D 3 alcohol ACE inhibitors, statins-HMG-CoA reductase inhibitors Flavonoids, silymarin, green tea polyphenols, curcumin, capsaicin, flavopiridol Deoxyspergualin, geldanamycin, retinoids, vitamin D analogues Proteasome inhibitors: velcade, lactacystine, epoxomycin, peptide aldehydes a Early in macrophages, nitric oxide induces NF-k B, but later it inhibits it mucosal epithelial cells. Actually, Bacteroides species activate perioxisome proliferator-activated receptor-g (PPAR g ) receptors, which take RelA out of cell nuclei of the gastrointestinal (GI) epithelium. Hence, cytokine production via NF-k B is suppressed [58] . Clearly, inflammatory reactions at the gut mucosa can cause much trouble. Hence, note that local GI macrophages show downregulation of their TREM1 (triggering receptors expressed on myeloid cell 1)-activating receptors. TREM would amplify cytokine-induced responses. This is explained by the local environment, in which there is plentiful IL-10 (suppressive cytokine) and transforming growth factor-b (TGF b ) [59] .

Enhanced NF-k B activity occurs in the gut mucosa in inflammatory bowel diseases. In Crohn's disease, there is high expression of the immunoproteasome so that there is enhanced processing of the p105 → p50 and enhanced degradation of inhibitor I k B a . Then p50/c-Rel is important for IFN g induction of proteasomes via IL-12-driven Th1 cell responses [60] .

Phosphorylation of cRel is needed for antiviral responses. Accordingly, TBK1 (Tank binding kinase-1) and IKK e phosphorylate the C-terminal of cRel so that p50/cRel can bind at NF-k B sites [61] . TBK also phosphorylates IRF3. This means that interferors IFNα /β are induced (Chap. 14) [62] .

Anti-inflammatory cytokines IL-10 and IL-13 suppress the activation of NF-k B. Unlike many cytokines, IL-10 does not activate the NF-k B. Heat shock proteins inhibit NF-k B by stopping the degradation of I k B [22c] . There is accumulating information on drugs and antioxidants like N-acetylcysteine [63] , resveratrol of red wine or the polyunsaturated fatty acid (PUFA) conjugated lineoleic acid (CLA) [64] that inhibit NF-k B activation and thus have anti-inflammatory properties.

Those with therapeutic inclinations will be interested in physiological mediators and drugs that can be used to inhibit NF-k B (Table 11 .2). The immunosuppressant cyclosporin stops RelA activation and so reduces IL-2 formation by T lymphocytes [65] . Decoy deoxynucleotides or negative mutants of NF-k B are used by the biochemist. A recent review of pharmacological aspects of NF-k B [66] listed inhibitory peptides for NF-k B that have been used in anti-inflammatory exploration. The cyclopentenone 15-deoxyPGJ2 is anti-inflammatory by virtue of its ability to modulate TFs [67] . It also acts to potentiate nitric oxide (NO), stopping neutrophil ingress.

In this amazing list of diverse agents, note that T regulatory (suppressor) lymphocytes act, in part, by inhibition of NF-k B. Thus, Li et al. [68] demonstrated how suppressor lymphocytes stop the presentation of CD86 on antigen-presenting cells (APCs). I k BNS is an inhibitor that binds to nuclear Rel/p65. It accounts for negative selection of thymocytes [69] and T lymphocytes or macrophages [32b] .

Dendritic cells (DCs) use NF-k B for their maturation, and they use NF-k B to help form Th1 lymphocytes and CD8 cytotoxic T cells. NF-k B p50-RelA determines the differentiation of DCs and their survival, and their formation of IL-12 depends on NF-k B p50-cRel [70] . Not surprisingly, we know of numerous microorganisms that are able to subvert NF-k B activation to gain entry into the body [71] . Conversely, if there is p38 MAP kinase activation, that will lead to NF-k B induction of inflammatory genes [72] . NF-k B supports adaptive immunity and the elimination of microbial invaders.

Glucocorticoids, on that list, are immunosuppressive agents. Their glucocorticoid receptors (GRs) suppress the activity of CREB-binding protein (CBP)/p300 induce corepressors like histone deacetylase 2 (HDAC2) [73] . Similarly, PGE2 is antiinflammatory by virtue of the fact that it enhances the expression of I k B a , and ineffectual p50/p50 homodimers form [74] . It turns out that 1,25(OH)2 vitamin D 3 and 1,24(OH)2D2 inhibit TNF a expression by macrophages. What is more, these forms of vitamin D increase the activity of I k B a ; thus, they inhibit NF-k B activity [75] .

Obviously, using PPAR g and -a agonists (Fig 4.14) is a way of dealing with inflammation. PPAR a knockout mice show augmented inflammation. In them, there is marked expression of TNF a and IL-1 b and expression of Fas ligand in the course of carrageenan-induced paw oedema or carrageenan-induced pleurisy [76] .

The involvement of effector molecules in physiological or pathological processes can now be elucidated or confirmed by the use of gene knockout (ko) or transgenic (tg) mice, into which an extra gene is inserted. Already, examples have been mentioned. Mouse models that lack almost all the known genes for G protein a -subunits have been generated to give insight into G protein signal pathways. G a q-deficient platelets fail to aggregate in response to thrombin, adenosine diphosphate (ADP) or thromboxane A2 (TxA2) due to lack of agonist-induced phospholipase C activation. Mice lacking G a q have increased bleeding times and are protected against thromboembolism. Mice with knockout of gene granulocyte-macrophage colony-stimulating factor (GM-CSF) develop silting of the lungs by "alveolar proteinosis", which is a clear indication of the cause of this rare condition. Transgenic mice that overexpress phospholipase A2, which generates leukotrienes and platelet-activating factor (PAF) ( Fig.  6.2b ) , develop exuberant atherosclerosis. They show enhanced oxidation of their plasma low-density lipoprotein (LDL). Mice that lack neutrophil elastase (NE) cannot clear infections with intracellular bacteria [77] . Mice deficient in cathepsin G succumb to Staphylococcus aureus [78] . The subtleties of NF-k B controls are gradually being elucidated by techniques like this (cf. [79] ). B lymphocytes with RelA −/− deficiency were killed easily by exposure to TNF a since they had reduced expression of Flice (i.e. caspase 8) and of Bcl-2 antiapoptotic protein. Clearly, NF-k B enables B cell survival by eliminating the effects of TNF a toxicity. This may remind one that c-Flip , inhibitor of the extrinsic apoptotic pathway, is known to promote NF-k B signalling and cell survival [80] . RNA interference (RNAi) is a mechanism for sequencespecific posttranscriptional inhibition of gene expression acting on double-stranded RNA molecules. Small interfering RNAs can be applied to mammalian cells. Thus, RNAi was used to show how phospholipase D (PLD-1) colocalises with actin filaments at the adhesive surfaces of macrophages [81] . RNAi has been used to assess the role of p50 NF-k B1 protein in the maturation of monocyte-derived DCs. siRNA for p50 reduces the transcription of IL-12 p40. Absence of NF-k B1 p50 or of c-Rel leads to impaired survival of DCs and lack of IL-12 production. IL-12 production in macrophages is blocked when the IFN g receptor or the TNFRI are removed by gene deletions in mice. NF-k B2, p52, derived from precursor p100, when eliminated in knockout mice, results in DCs with enhanced RelB activity. Enhanced RelB is accompanied by enhanced MHC class II molecule expression on APCs and an increased ability to induce CD4 lymphocytes (Table 11 .3 ) .

Various pathways help to stimulate the expression of Cox-2, such as ROS, tumour promoters, growth factors, oncogenes, and cytokines. Her2/Neu related to the epidermal growth factor receptor (EGFR) does this in breast cancer. Also, in breast and colon cancers there is activation of NFAT (nuclear factor of activated T cells), which leads to Cox-2 induction and so formation of PGE2. Tumours with elevated Cox-2 will be invasive [82] . Indeed, typical metastatic gene products are Cox-2, intercellular cell adhesion molecule 1 (ICAM1), vascular endothelial growth factor (VEGF), and metalloproteinase 9 (see Chap. 18).

Generally, transcription of Cox-2 gene is promoted by PKC, Ras signalling, and especially MAP kinase induction of NF-k B and C/EBP and factors that stimulate activator protein 1 (AP-1) [83, 84] ( Fig. 11.3 ) . This is similar to induction of cytokines. Consider the situation when Helicobacter pylori causes chronic gastritis. Study of TFs in gastric epithelial cells showed Cox-2 promoter induction by NF-k B, AP-1 and C/EBP (NF -IL-6) [85] . In Fig. 11 .3 , note the canonical TATA motif and several important enhancer elements affected by transactivators. Proinflammatory mediators can activate ribosomal S6 kinase (RSK), which enhances C/EBP b binding to the Cox-2 promoter. Sphingosine-1-P , by stimulation of NF-k B, also stimulates Cox-2 activity [86] .

Cox-2 expression in neutrophils is promoted by ROS induction of NF-k B in response to cell membrane events [87] . Likewise, when monocytes interact with Table 11 .3 How nuclear factor kappa B (NF-k B) supports antiapoptosis/cell survival NFkB supports: Inhibitor of apoptosis proteins 1 and 2 and c-FLIP , which inhibit caspase 8 Protein A1 and Bcl-Xl , which stop mitochondrial release of cytochrome C A20 protein, which thwarts (a) IKK, (b) RIP and (c) TAK1 (Fig. 11 .2) XIAP GADD45 b , which inhibits JNK FHC, which stops ROS stimulation of JNK FHC ferritin heavy chain, GADD45 growth arrest and DNA damage 45, IKK unit I-kappa B kinase, JNK Jun N-terminal kinase, ROS reactive oxygen species, XIAP X chromosome inhibitor of apoptosis TAK1 = transforming growth factor b-activated kinase 1. platelets or P-selectin-coated surfaces, there is activation of NF-k B and so Cox-2. In a second phase, IL-1 stabilizes the Cox-2 messenger RNA (mRNA), which it does by silencing of the binding protein ARE ; thus, there is enhanced translation [88] . Induction of Cox-2 in macrophages is also biphasic and requires C/EBP b and C/EBP d TFs [89] . Conserved elements in the macrophage Cox-2 gene promoter as revealed by analysis after exposure to LPS are -CRE2/NF-k B-C/EBP/AP-1/CRE1/ E-box-TATA. The E-box mediates transcriptional repression, whilst the other ciselements are activating. At 6 h after LPS administration, Cox-2 gene transcription was completely dependent on phospho-c-Jun along with the p50 of NF-k B [90] . One can compare this information with the details of the promoter for Cox-2 in airway smooth muscle cells.

With regard to the discussion in Chap. 4 (Sect. 4.3.1), one can expect that there will be histone acetylation on H3/H4 at the Cox-2 promoter and phosphorylation of H3 histones.

There are different patterns of histone H4 acetylation induced by IL-1 b or by bradykinin. Whereas IL-1-induced transcription utilises NF-IL-6, NF-k B and CRE, bradykinin uses CRE [91] . Induction of Cox-2 in macrophages is complicated. Normally, any response to NF-k B activation is rapid. Full Cox-2 expression in macrophages is delayed since there first has to be induction of TNF a by IFN g [92] . In mesangial cells, TGF b is able to stimulate Cox-2 [93] . When mouse macrophages respond to virus or double-stranded RNA (dsRNA), there is selective induction of Jun N-terminal kinase (JNK) and p38 and therefore activation of NF-k B that activates Cox-2 [94] .

As a lesson, consider how the peptidoglycan of bacterial cell walls stimulates TLR2 receptors; hence, there is NF-k B activation that activates Cox-2, and PGE2 is produced. This PGE2 then acts on EP2/EP4 surface receptors of the macrophages, so that cAMP is produced and protein kinase A is activated, which then accounts for Ser276 phosphorylation on the p65 of NF-k B. The consequence is that peptidoglycan elicits the secretion of IL-6 [95] . PGE2 induction of Stat3 is operative in this process [96] . 

Transactivation of a particular gene requires a large complex of proteins ( Figs. 4. 8, 4.19 ) . In their inactive state, PPARs are complexes in the cell cytoplasm along with corepressor proteins. On activation, they dissociate and move into the nuclei, where PPARs form heterodimers with retinoid X receptors ( Fig. 4.14 ) . PPAR g receptors are highly expressed in macrophage-derived foam cells in atheroma. It was found that PPAR g receptors are involved in the differentiation of monocyte macrophages, and that PPAR g receptors help to regulate their inflammatory activities [97] . In macrophages, PPAR g serves as a stimulus for the anti-inflammatory action of carbon monoxide. PPAR g will promote the survival of lymphocytes since they suppress ROS by boosting antioxidants, and they attenuate any decline in adenosine triphosphate (ATP) [98] . Yet, fatty acid ligands for PPAR g can inhibit proliferation of activated T lymphocytes through inhibition of IL-2 formation and induced T cell apoptosis. The PPAR g associates with NFAT, so the DNA binding and transcriptional activation of the IL-2 promoter is blocked. Also, PPAR g receptors are expressed on DCs, and PPAR g ligands inhibit the release of IL-12 [99] . DCs treated with synthetic PPAR g ligands have reduced ability to stimulate lymphocytes. People are getting excited about the potential use of PPAR g ligands in conditions like rheumatoid arthritis [100] . PPAR g agents will decrease synovial production of TNF a , IL-6, IL-8, metalloproteinases [101] and no doubt IL-12 ( Fig. 12.12) .

Both PPARs and liver X receptors of the nuclear-receptor superfamily function in combination with the GRs to repress inflammatory response genes [102] . NCoR (nuclear receptor corepressor) and SMRT corepressor complexes, which are able to interact with NF-k B and AP-1, maintain the repression of inflammatory response genes (cf. Fig. 11.4 ) . PPAR a receptors respond to a different set of ligands/drugs. PPAR a receptors are also expressed on monocyte macrophages, and ligands can induce apoptosis of those cells. PPAR a receptors dampen endothelial cell inflammatory responses. In aged mice, oxidative stress-induced NF-k B is apparent in many tissues. Fortunately, PPAR a agonists restore the cellular redox balance, so there is amelioration of the production of inflammatory cytokines [103] since NF-k B is inhibited (cf. Fig 11.4 ) . Fenofibrate has been shown to repress IL-17 expression in cultured splenocytes and by Th-17 cells exposed to caecal bacterial antigens. Of course, if liver X receptors will suppress inflammatory genes, appropriate agonists will have enormous potential. Cytokine release by monocytes in response to LPS has been investigated [104] . As yet, it is not clear how the process operates.

Survival of a cell depends on a supply of growth factors from serum and on contact with neighbouring cells or adherence to extracellular matrix proteins [105] . The ERK pathway ( Fig. 4.3 ) has the capacity for survival induction but is negatively regulated by phosphatases in conjunction with the proapoptotic p38/JNK paths. Hence, cancer cells should not emerge. Protein kinase B (Akt) confers the attributes of cell survival [106] . PI3 kinase (PI3K) produces PtdIns(3,4,5)P3 ( Fig. 2.6 ) , which binds to Akt so that it can translocate to the cell membrane, where it is phosphorylated by 3-phosphoinositide-dependent kinase 1 (PDK-1). When IL-2 acts on immune cells, Akt ensures their survival. Either a growth factor like PDGF (plateletderived growth factor) or a cytokine like TNF a will activate Akt, which then associates with and phosphorylates IKK so that NF-k B is activated. Concurrently, Akt suppresses proapoptotic influences [107] . Akt sequesters the proapoptotic protein Bad, it inhibits caspase 9, and it reduces transcription of Fas ligand (cf. Fig. 8.3 ) . Conversely, since ceramide-activated PKC z and protein phosphatase 2A (PP2A) negatively regulate the Akt survival pathway [108] , this explains how ceramide often mediates cell apoptosis. Nevertheless, the a 4-subunit of PP2A (and other phosphatases) works to keep apoptosis in check and to maintain cell survival [109] .

It will help to be precise about what Akt can contribute . Akt can inactivate (a) death receptor-mediated apoptosis, (b) mitochondrial-dependent apoptosis and (c) p53-induced apoptosis. Akt via Cot serine-threonine kinase activates NF-k B. NF-k B supports antioxidant enzymes. Akt phosphorylates glycogen synthase kinase 3 b (GSK3 b ), ensuring glucose uptake and metabolism. GSK3 is important in embryonic development. When Akt promotes the survival of adult cells, Akt phosphorylates and inhibits GSK3 [110] and thus enables supportive changes in glucose metabolism. GSK3 b is essential for cell survival, but too much or too little will cause apoptosis. On the one hand, components of the NF-k B system are phosphorylated by GSK3 to promote NF-k B activity. Conversely, if p53 binds nuclear GSK3, it is activated and promotes the transcriptional and apoptotic actions of p53 [111] . GSK3 supports formation of proinflammatory cytokines by inducing NF-k B and CREB interaction with coactivator CBP. GSK3 inhibitors are thus anti-inflammatory [112] .

Both growth factor and cytokine survival factors for cells, like insulin-like growth factor 1 (IGF-1) or IL-3 activate Akt, which phosphorylates Bad at three sites, and it then binds 14-3-3 protein, and it (Bad) is sequestered in the cytosol. So, apoptosis cannot occur. When macrophages meet endotoxin, they have to survive. When LPS interacts with TLR4 receptors ( Figs. 12.2, 12.5 ), RIP links TLR4 to PI3K and so to Akt and cell survival [113] . Monocyte survival derives from surface CEACAM1 (CD66a), which connects with PI3K and hence to Akt activation.

Insulin growth factors I and II direct protein anabolism, and they are mitogens. Haemopoietic cells that are destined to die when IL-2 or IL-3 is withdrawn are protected by IGF-1. IGF-1 is antiapoptotic for many cells [114] , and in many cancers an autophosphorylated IGF-1R (IGF-1 receptor) mediates antiapoptosis. The biochemical scenario is that when IGF-1 acts on its IGF-1R there is recruitment of a docking protein insulin receptor substrate 2 (IRS-2) (as for insulin) and that leads to activation of PI3K. PI3K activates a PDK-1, and in turn that activates Akt kinase. Naturally, the kinase-regulated signalling pathways are controlled by phosphatases. One is calcineurin, which will dephosphorylate Bad and so reverse the effect of Akt phosphorylation. The other is PTEN (phosphatase as in Fig. 2.6) , the product of a tumour suppressor gene [115, 116] . The function of PTEN is to hydrolyze 3-phosphorylated inositol phospholipids [117] . Thus, PTEN acts in opposition to PI3K ( Fig. 2.6 ). In malignancies, both copies of PTEN are deleted or mutated. Loss of PTEN in cells leads to Akt drive, and this is accompanied by resistance of cells to apoptotic stimuli [118] . Hence, cancer is likely to arise.

There are other survival kinases, suppressors of Myc-induced apoptosis, called the Pim kinases [119] . Myc induces proliferation but also increased apoptosis of nonmalignant cells. However, defects in control of apoptosis allow Myc to act as an oncogene. Akt or Pim control this. Both Akt and Pim inactivate Bad. Pim kinases are implicated in cancers and lymphomas. Pim kinase was discovered by its ability to stop Myc-induced apoptosis in a mouse model of lymphoma. Cytokines via Jak -Stat action (Sect. 12.9) induce Pim kinases (Pim1, -2, -3) .

This section emphasizes the importance of NF-k B for cell survival. NF-k B suppresses apoptosis ( Fig. 8.2 ) since NF-k B supports bcl-2 and bcl-Xl, it supports the inhibitor of apoptosis proteins cIAPc and xIAP , and c-FLIP works in its favour [120] it room. Yet, the JNK cascade can work in opposition to the (GADD45) and Xiap proteins, which promote antiapoptosis [120] (Table 11 .3). Likewise, the p38 MAP kinase pathway is proapoptotic [121, 122] . Actually, induction of NF-k B in some cells enables them to stay alive long enough to acquire genetic errors. Hence, NF-k B activity can promote carcinogenesis [5] and help metastases [123] . Such carcinogenesis is oxygen radical mediated [124] . Yet generally, NF-k B is acting to suppress tumour cell growth for it aids triggering of p53 and ARF (Fig. 17.5) . However, if cells lose their tumour suppressor genes, NF-k B then promotes oncogenesis [125] .

Insulin is a potent anabolic hormone. Whereas glucose elicits proinflammatory effects, insulin is anti-inflammatory for its action suppresses NF-k B, AP-1 and early growth response 1 (EGR-1) TFs. Of course, insulin is a principal pancreatic autoantigen relevant to diabetes [126] . Yet, one could be interested in how signalling by the insulin receptors compares with other mechanisms discussed in this text.

Insulin receptor stimulation in insulin-responsive cells leads to translocation of GLUT4 and glucose transport. The insulin receptor is an a 2 b 2 heterotetrameric complex in which two a -subunits and two b -subunits are linked by disulphide bonds. Insulin binds to the extracellular a -subunits, and it thereby transmits a signal across the plasma membrane that activates the intracellular tyrosine kinase of the b -subunit. The one b -subunit phosphorylates its partner on specific tyrosine residues. Accordingly, the receptor tyrosine kinase induces phosphorylation of IRSs on multiple tyrosine residues. These IRS phosphotyrosine residues act as docking sites for −SH2 domain containing proteins, including the p85 regulatory unit of PI3K ( Fig. 2.7 ) . Hence, the p110 catalytic unit of PI3K, the lipid kinase unit, will lead to glucose transport [127, 128] . Other proteins that dock at the insulin receptor include adaptor proteins Shc and Grb2 (growth factor receptor-bound protein), leading to Ras-MAP kinase signalling for the mitogenic action of insulin, the SHP2 phosphatase [129] and Cbl (casitas B lineage lymphoma protein).

The PI3K (Fig. 11 .5) p110 catalytic unit creates phosphoinositides PI(3,4,5)P3 , PI(3,4)P2 and PI(3)P at the plasma membrane ( Fig. 2.6 ). They increase GLUT4 translocation but do not actually increase glucose transport. That could be mediated by AS160 (Akt substrate of 160 kDa) [130] . The plasma membrane target for the GLUT4 vesicle is the t-SNARE called syntaxin 4. Inactivation of Glut4 in muscle leads to raised plasma glucose and glucose toxicity that results in insulin resistance [131] . Insulin action is facilitated by the formation of ROS at multiple signalling targets [132] , but substantial ROS produced in response to TNF a or dexamethasone creates insulin resistance [133] .

There is subtle control by suppressor of cytokine signalling (SOCS) proteins. First, SOCS3 reduces the phosphorylation of IRS-1 and its subsequent association with the p85 of PI3K. Second, the SOCS1 and -6 can inhibit insulin receptor tyrosine kinase activity, thereby reducing the phosphorylation of IRS-1/2 and the downstream events. IRS-1 and IRS-2 are targeted for proteasomal degradation. SOCS1 and -3 are elevated in rodent models of insulin resistance and diabetes.

In adipocytes of obese persons with type 2 diabetes, IRS-2 becomes the main docking protein for PI3K [134] . Local TNF a acting on the adipocytes is a cause of insulin resistance [135] . Ganglioside GM3 on fat cells corresponds to insulin resistance. TNF a -induced insulin resistance involves activation of inhibitory serine kinases or tyrosine phosphatases, which inhibit the insulin signalling path. It works through H 2 O 2 generation. Also, there is serine phosphorylation of IRS-1, rather than IRS-1 tyrosine phosphorylation, that causes reduced insulin receptor kinase activity. In skeletal muscle, TNF a inhibits Akt phosphorylation, causing insulin resistance [136] . Ceramide, by blocking insulin stimulation of Akt, leads to insulin resistance [137] . TNF a can also produces insulin resistance in skeletal muscle by activation of I k B kinase inhibitor of NF-k B in a p38-dependent manner [138] . Most particularly there is upregulated JNK which impairs the action of IRS 1/2 [138b] .

Crucially, we now realize that adiponectin receptors mediate antidiabetic metabolic effects. Adiponectin promotes glucose uptake, fatty acid oxidation and PPAR a ligand activities. Adiponectin is decreased in obesity, in type 2 diabetes and whenever there is insulin resistance [139] . There is more interest in adipokines from fat stores. The cytokine "resistin" inhibits insulin signalling in liver and muscle in mice [140, 141] .

Insulin resistance is essentially due to decreased insulin-stimulated glucose uptake into skeletal muscle. The muscle PI3K (with its p110 catalytic unit and p85 regulatory unit) actually shows increased transcription of the p85 a and of splice variants p55 and p50, and the increase of these subunits must reduce PI3K activity by competing for phosphotyrosine targets [142] . Insulin resistance is accompanied by endothelial cell dysfunction, and there is enhanced aggregability of platelets. Insulin-resistant macrophages are integral to the problem of metabolic syndrome [143] . When they are controlled by knockout of JNK1, insulin resistance is ameliorated, and mice are resistant to high-fat diet-induced obesity [144] .

Colca [145] rationalized the complex situation by proposing that insulin resistance is a physiological compensation to excessive oxidative metabolism. A new successful set of antidiabetic drugs, the thiazolidinediones (TZDs) [146] , enhances PPAR g -retinoid X receptor heterodimer formation ( Fig. 4.14 ) and offsets insulin resistance.

Insulin and angiotensin II (Ang II) play pivotal roles in the metabolic and circulatory systems. Failure in their proper actions leads to diabetes mellitus and hypertension, respectively [147] . There is cross-talk at multiple levels between these systems that affects the action of antihypertensive drugs used in the control of cardiac hypertrophy and energy acquisition by heart muscle. Thus, insulin actually promotes a significant increase of AT1 receptor protein expression in vascular smooth muscle cells (cf. Fig. 5.10 ). The insulin signalling system described stems from a balance between tyrosine phosphorylation of IRS-1 and the negative effect of IRS-1 serine phosphorylation.

Too much of the latter occurs in insulin resistance (Fig. 11.5 ) . In fact, PI3K, ERK and JNK as activated by AngII catalyse the serine phosphorylation of the insulin receptor and the IRS-1, and indeed of PI3K, impairing insulin-promoted activation toward Akt. Hence, in contrast to the effect of insulin, IRS-1/2-associated PI3K activity, and thereby endothelial nitric oxide synthase (eNOS) activity, is inhibited by Ang II in a dose-dependent manner [148] . So, insulin-induced vasodilatation is thwarted by Ang II. Furthermore, Ang II induces SOCS3 activity to impair signal transduction through the Jak2/Stat5 signal pathway [149] .

mTOR is mammalian target of rapamycin. It is an integrator of cellular energy status, nutrient and growth factor signals and the coordinator of cell growth and cell cycle progression [150] . TOR directs cell surface expression of various nutrient transporters. Amino acids also stimulate mTOR via the class 3 PI3Ks [151] . Since insulin and IGF-1 are anabolic, Fig. 11 .6 shows how those receptors connect via IRS proteins to activation of PI3K and hence Akt. In its turn, Akt phosphorylates and inhibits substrates like the Foxo (Forkhead TFs), Bad, GSK3 and tuberin or hamartin. Tuberin, characteristic of benign tumours called hamartomas as seen in tuberose sclerosis [152, 153] , inhibits TOR, but tuberin is inhibited by Akt. This means that Akt activity stimulates glucose uptake and cell growth and proliferation, and apoptosis is inhibited. Actually, mTOR exerts negative feedback on PDGF receptors [154] . The TOR pathway requires nutrients like the amino acid leucine, and then Tor complex 1 (mTORC1) activates S6 kinase and promotes the eukaryotic translation initiation factor 4E (eIF4E) [155] . Additionally, mTORC2 regulates polarization of the actin cytoskeleton. Furthermore, should cell ATP levels fall, the energy-sensing kinase AMPK inhibits hepatic gluconeogenesis ( Fig. 1.1 ) because it promotes TORC2 phosphorylation, which blocks its nuclear accumulation [156] . AMPK is a fuel sensor. In muscle AMPK is activated by exercise [157] . It is a key metabolic regulator in liver, heart and muscle. AMPK is activated by cell cAMP, and it will stimulate fatty acid b -oxidation. That means that if hepatic AMPK is inactivated, as occurs in diabetes, there is fatty acid synthesis and development of hyperlipidaemia. In T cells, AMPK controls metabolic steps required for cell proliferation [158] .

The tuberose sclerosis 1 and 2 (TSC1-TSC2) protein complex heterodimers integrate cues from growth factors, the cell cycle and nutrients to regulate the activity of mTOR, p70 S6 kinase, 4E-BP1 → eIF4E and ribosomal S6 protein [159] . As you will predict, hypertrophy of cells is achieved by augmentation of their RNA and protein content. Formation of mRNA is determined (a) by growth factor Ras-ERK -Mnk-1 → eIF4E and (b) by the path mTOR → p70 S6 kinase.

Note that these molecules in Fig. 11 .6 do not form a linear signal pathway, but they act as agonists and antagonists of each other's activities. Stimulation of mTOR and S6 kinase by amino acids requires participation of a class 3 PI3K called hvps34 (human vacuolar protein sorting 34) [160] . PI3Ks promote glycolysis and thus production of ATP. As in other situations, PTEN controls PI3K activity. Loss of PTEN in mice leads to hyperactive signalling to TOR and disturbance of the control of haemopoietic stem cells and a liability to leukaemia [161] . Understandably, mTOR must be implicated in carcinogenesis [162] .

GSK3 b inhibitors are anti-inflammatory, witness that inhibitors like thiazolidinediones (TZDS) attenuate carrageenan-induced lung injury [163] .

In T cells, Akt is activated maximally when there is coligation of the TCR and CD28 ( Fig. 13.5 ) . Moreover, T cells have AMPK a 1, which is rapidly activated with TCR triggering via the adapter molecules LAT and SLP76 ( Fig. 13.4 ) [164] . When amino acids are supplied, mTOR phosphorylates components of the translational apparatus like the eukaryotic initiation factor eIF4E and p70 S6 kinase. Cytokines also induce PIM1/PIM2 kinases, which help maintain a high rate of glycolysis and protein translation [165] .

Rapamycin is a useful immunosuppressant for allograft transplants. Yet, rapamycin does not phenocopy the effects of nutrient or growth factor deprivation. Actually, it fails to prevent the early stages of T lymphocyte activation, including cell cycle entry and upregulation of cell surface activation markers. Outstandingly, rapamycin, by its inhibition of mTOR and thereby of the phosphorylation of S6 kinase and eIF, prevents cell hypertrophy of a remaining kidney after unilateral nephrectomy [166] .

S6 kinase is integral to multiple pathways in which cells are rendered unresponsive to insulin, as during chronic insulin exposure, elevation of free fatty acids and perhaps TNF a exposure. A feedback leads to IRS1/2 serine phosphorylation and hence downregulation. Accordingly, there is insulin resistance and impaired cell survival.

Chronic localised activation of mTOR results from genetic loss of certain tumour suppressor genes like TSC1, PTEN in Cowden's disease and 1KB1 (Peutz-Jegher's syndrome) [167] .

Armed as we are now with so much new knowledge, we can tackle the question of how alveolar macrophages (AMs) survive so well, even though they are exposed continually to chemical pollutants, ROS, inflammatory mediators and microbial invaders. In fact, AMs have two survival pathways: (a) the PI3K → Akt pathway and (b) ERK activity that leads to inhibition of proapoptotic proteins but good antiapoptosis. The Hunninghake group [168] investigated how it is that ERK activity leads to sustained protein translation initiation via eIF4E or hypophosphorylated (active) eIF2 a . Actually, ERK decreases proapoptotic JNK activity by stabilizing MPK7 dual phosphatase. When JNK activity is low, there is higher activity of phosphatase PP1 a . Accordingly, there is hypophosphorylation of translation initiation factor eIF2 a , so there is ongoing protein translation that means survival of the AMs.

The Rel/NFkB family: friend and foe

Nemo oligomerization in the dynamic assembly of the IkappaB kinase core complex

Proteasome independent functions of ubiquitin in endocytosis and signaling

Ubiquitin: tool and target for intracellular NF-kB inhibitors

New insights into NF-B regulation and function

Nuclear Factor Kappa B: regulation and function

Nuclear factor kB: its role in health and disease

Nuclear factor kappa-B

The two NF-kB activation pathways and their role in innate and adaptive immunity

NFkB as a primary regulator of the stress response

Function and activation of NFkB in the immune system

Inhibitors of PKC prevent activated transcription: downstream of NFkB DNA binding

Antioxidant and redox regulation of gene transcription

Redox regulation of cellular signalling

S-Nitrosylation: physiological regulation of NFkB

Regulation of Il-8 gene expression after phagocytosis of zymosan by human monocytic cells

Nitric oxide suppresses Il-8 transcription by inhibiting c-Jun terminal kinase induced AP.1 activation

Post-translational modifications of Nemo and its partners in NF-kB signaling

NFkB activation and complex formation with IkB kinase and NIK

The IKK complex: an integrator of all signals that activate NF-kB

NFkB inducing kinase activates IKK a by phosphorylation of Ser176

Positive and negative regulation of IkB kinase activity through IKK b subunit phosphorylation

Oscillations in NFkB signaling control the dynamics of gene expression

The Ying and Yang of NF-kB activation

Diversity and regulation in the NF-kappaB system

Hydrogen peroxide Prolongs nucleus localization of NF-kB in activated cells by suppressing negative regulatory mechanisms

Innate immunity meets with cellulur stress at the IKK complex: regulation of the IKK complex by HSP10 and HSP 9d

p38 MAP kinase controls NF-kappaB transcriptional activation and TNF a production

Proinflammatory IKK a phosphorylation of PIAS1 to restrict inflammation and immunity

MK2 controls the level of negative feedback in the NFkappaB pathway

Caught between CYLD and Charybdis

Dual role for RhoA in suppression and induction of cytokines in the human neutrophil

Extending the nuclear roles of IkB kinase subunits

Regulation and function of IKK and IKK-related kinases

A regulator (IKK a ) branches out

Promoter dependent effect of IKK a on NF-kappaB/ p65 DNA binding

IKK a in regulation of inflammation and adaptive immunity

New regulaters of NF-kB in inflammation

IKK a limits macrophage NFkB activation and contributes to resolution of inflammation

NF-κB links immunity to the hypoxic response through transcriptional regulation of HIF-1a

NF-kB is a negative regulator of Il-1beta secretion as revealed by genetic and pharmacological inhibition of IKK b

An anti-inflammatory role for IKKβ through the inhibition of classical macrophage activation

IKKβ/NF-kB and the miscreant macrophage

Lymphotoxin receptor induces sequential activation of distinct NFkB factors via separate signaling paths

Cellular interactions in lymph node development

NF-kB2 for establishment of central tolerance through an Aire dependent pathway

The IkB function of NFkB2 p100 controls stimulated osteoclastogenesis

NF-kB inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis

Skin controls immune regulators

Negative regulating of T cell receptor signaling by NFkB2/ p100

Alternative regulation of NFkB

MAPkinase p38 regulates transcriptional activity of NF-kB in primary human astrocytes via acetylation of p65

Regulation of NFkB transcription factor complex by acetylation

Oxidative stress augments production of MMP1, Cox2 and PGE2 through enhancement of NFkB in LPS activated human monocytes

Endotoxin tolerance inhibits lipopolysaccharide initiated acute pulmonary inflammation and lung injury in rats by the mechanism of NFkB

Induction of Rel B participates in endotoxin tolerance

Endotoxin tolerance attenuates LPS induced TLR4 mobilization to lipid rafts

Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function

IkB-z as a regulator of NF-kB activity

Bcl-3 and NFkB p50 attenuate lipopolysaccharide induced inflammatory responses in macrophages

Negative regulation of TLR signaling by NFkB p50 blockade ubiquitination

Bcl-6 regulates chemokine gene transcription in macrophages

Control of inflammation, cytokine expression and germinal centre formation by Bcl-6

Bcl-6 interacts with transcription factor Miz-1 to suppress the CDKI p21 and cell cycle arrest in germinal centre B cells

Genetic and epigenetic factors involved in B cell lymphomagenesis

Mutations of the Bcl-6 protooncogene disrupt its negative autoregulation in diffuse large B cell lymphoma

Compartmentalising NF-kappa B in the gut

Macrophages expressing triggering receptor expressed on myeloid cells-1 are underrepresented in the human intestine

Proteasome mediated degradation of IkB a and processing of p105 in Crohns disease and ulcerative colitis

Nuclear accumulation of c-Rel following C-terminal phosphorylation by TBK1/IKK e

Turning NF-κB and IRFs or and off in DC

N-Acetylcysteine blocks mesangial VCAM-1 and NFkappa B expression in vivo

Conjugated linoleic acid suppresses NFkB activation and Il-12 production in dendritic cells

Cyclosporin inhibits the early phase of NFkB/RelA activation induced by CD238 costimulation signaling to reduce Il-2 expression in human peripheral T cells

From willow bark to peptides: the ever widening spectrum of NFkB inhibitors

15Deoxy-PGJ2 as potential endogenous regulator of redox-sensitive transcription factors

T suppressor lymphocytes inhibit NFkB mediated transcription of CD86 gene in antigen presenting cells

Peptide induced negative selection of thymocytes activates transcription of an NFkB inhibitor

Dendritic cells require distinct NFkB subunits

Subversion and utilization of the NFkB pathway during infection

p38 dependent marking of inflammatory genes for increased NFkB recruitment

Glucocorticoids: effects on gene transcription

Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of NF-kB subunits

The anti-inflammatory activity of 1,25 dihydroxyvitamin D3 in macrophages

The role of PPAR-alpha in the regulation of inflammation

Mice lacking neutrophil elastase reveal impaired host defence against gram-negative bacterial sepsis

Killing activity of neutrophils is mediated through activation of proteases by potassium flux

Oncogenes, tumour suppressors and p52NFkB

Caspase 8 inhibitor FLIP promotes activation of NFkB and ERK signaling pathways

PLD-1 regulates phagocyte adhesion

NFAT induces breast cancer cell invasion by promoting the induction of Cox2

The sphingosine kinase:sphingosine-1-phosphate pathway mediates Cox.2 induction in response to TNF a

Modulation of IgE dependent Cox2 gene expression by reactive oxygen species in human neutrophils

Cyclooxygenase 2 expression by transcription factors in H. pylori infected gastric epithelial cells

G a 12 regulates Cox-2 induction by sphingosine-1-phosphate

Expression of Cox2 in platelet-monocyte interactions involving adhesion and cytokine signaling

Reactive oxygen species from mitochondria induce Cox-2 gene expression in human mesangial cells

The induction of Cox2 in macrophages is biphasic

Cox2 gene transcription in a macrophage model of inflammation

Transcriptional regulation of Cox-2 by bradykinin and interleukin 1 beta in human airway smooth muscle cells: involvement of different promoter elements, transcription factors and histone H4 acetylation

Involvement of TNF a and NFkB in the transcriptional control of Cox-2 expression by IFN g in macrophages

TGF b 1 induces Cox2 expression and PGE2 synthesis in human mesangial cells

MAPK in regulation of ds-RNA and virus induced Cox2 expression by macrophages

Peptidoglycan induced Il-6 production in Raw 264.7 macrophages is mediated by Cox-2

Modulation of Stat3 activation by the cPLA2 and Cox2 controlled PGE2 signaling pathway

The role of PPARs in inflammation and immunity

PPAR g promotes lymphocyte survival via actions on cell metabolic activities

PPAR g activators inhibit interleukin 12 production in murine dendritic cells

PPAR g ligands as modulators of inflammatory and catabolic responses in arthritis

Functional changes in rheumatoid fibroblast synovial cells through activation of PPAR g signaling pathway

Combinatorial roles of nuclear receptors in inflammation and immunity

PPAR g activation modulates cellular redox status, represses nuclear factor-B signaling, and reduces inflammatory cytokine production in ageing

Liver X receptor regulator of cytokine release

Survival in three dimensions

10 years of protein kinase B signaling

PI 3-kinase downstream AKTion blocks apoptosis

Ceramide: second messenger or modulator of membrane structure

The PP2A associated protein a 4 is an essential inhibitor of apoptosis

Requirement for glycogen synthase kinase 3 in cell survival and NFkB activation

The glamour and gloom of glycogen synthase kinase-3

Toll-like receptor and cytokine production is differentially regulated by GSK3

RIP links TLR4 to Akt and is essential for cell survival in response to LPS stimulation

Regulation of survival signals from the IGF-1 receptor

The tumor suppressor PTEN regulates T cell survival and antigen receptor signaling

PTEN suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells

Modulation of cellular apoptotic potential: contributions to oncogenesis

PTEN: a new twist on b -catenin

Overexpression of Pim.1 during progression of prostate adenocarcinoma

Life or death decisions

The p38 signal transduction pathways

The p38 MAP kinase pathway suppresses cell survival by inducing dephosphorylation of MAP/ERK1,2

The transcription factor NFkB: control of oncogenes and cancer therapy resistance

The role of oxidative stress in carcinogenesis

NF-kB: tumour promoter/suppressor

Proinsulin: a unique autoantigen triggering auto-immune diabetes

The IRS signaling system: a network of docking proteins that mediate insulin and cytokine action

Signaling pathways in insulin action: molecular targets of insulin resistance

Regulation of the insulin signaling pathway by protein tyrosine phosphatases

Bridging the GAP between insulin signaling and GLUT4 translocation

Glucose toxicity and development of diabetes in mice with muscle specific inactivation of Glut4

Insulin antigen is facilitated by insulin stimulated ROS with multiple potential signaling targets

ROS have a causal role in multiple forms of insulin resistance

IRS-1 is reduced and IRS-2 is the docking protein for PI3kinase in adipocytes from subjects with NIDDM

TNF a and ceramide in insulin resistance

TNF a induces skeletal muscle insulin resistance via inhibition of Akt phosphorylation

Regulation of insulin action by ceramide

TNF a produces insulin resistance in skeletal muscle by activation of inhibitor kappa-B kinase

Jun N-terminal kinase pathways is diabetes

Cloning of adiponectin receptors that mediate antidiabetic metabolic effects

Vasocrine signalling from perivascular fat: mechanism linking insulin resistance to vascular disease

Increased p85/55/50 expression and decreased PI3kinase activity in insulin-resistant human skeletal muscle

The macrophage at the crossroads of insulin resistance and atherosclerosis

JNK1 in hematopoietically derived cells contributes to diet induced inflammation and insulin resistance

Insulin sensitizers may prevent metabolic inflammation

Glitazones: clinical effects and molecular mechanisms

The multi-faceted cross-talk between the insulin and angiotensin II signal systems

Crosstalk between the insulin and angiotensin signaling systems

SOCS3 provides a novel interface in crosstalk between angiotensin II and insulin signaling systems

Target of rapamycin (TOR)

Amino acids mediate mTOR signaling through activation of class 3 PI3kinase

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

The tuberose sclerosis complex

PDGF-receptors are critical for PI3kinase/Akt activation: negative regulation by mTOR

The expanding TOR network

The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism

AMPK: a key sensor of fuel and energy status in skeletal muscle

Signal transduction fuels T cell activation

eIF3:a versatile scaffold for translation initiation complexes

Hvps34 enters a growing game: mTOR complex 1/ S6K1 signaling

PTEN in the haematopoietic system and its therapeutic indications

Defining the role of mTOR in cancer

Inhibition of GSK-3 b attenuates development of carrageenan-induced lung injury

Regulation of the energy sensor AMP-activated protein kinase by antigen receptor and Ca 2+ in T lymphocytes

The Pim-kinases control rapamycin resistant T cell survival and activation

Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy

mTOR signaling: implications for cancer

Active ERK contributes to protein translation by preventing JNK-dependent of protein phosphatase-1